Literature DB >> 30281973

Clearance in Drug Design.

Dennis A Smith1, Kevin Beaumont2, Tristan S Maurer2, Li Di3.   

Abstract

Due to its implications for both dose level and frequency, clearance rate is one of the most important pharmacokinetic parameters to consider in the design of drug candidates. Clearance can be classified into three general categories, namely, metabolic transformation, renal excretion, and hepatobiliary excretion. Within each category, there are a host of biochemical and physiological mechanisms that ultimately determine the clearance rate. Physiochemical properties are often indicative of the rate-determining mechanism, with lipophilic molecules tending toward metabolism and hydrophilic, polar molecules tending toward passive or active excretion. Optimization of clearance requires recognition of the major clearance mechanisms and use of the most relevant in vitro and in vivo tools to develop structure-clearance relationships. The reliability of methods to detect and predict human clearance varies across mechanisms. While methods for metabolic and passive renal clearance have proven reasonably robust, there is a clear need for better tools to support the optimization of transporter-mediated clearance.

Entities:  

Year:  2018        PMID: 30281973     DOI: 10.1021/acs.jmedchem.8b01263

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  19 in total

1.  In Vitro - in Vivo Extrapolation of Hepatic Clearance in Preclinical Species.

Authors:  David A Tess; Sangwoo Ryu; Li Di
Journal:  Pharm Res       Date:  2022-03-07       Impact factor: 4.200

Review 2.  Successful and Unsuccessful Prediction of Human Hepatic Clearance for Lead Optimization.

Authors:  Jasleen K Sodhi; Leslie Z Benet
Journal:  J Med Chem       Date:  2021-03-25       Impact factor: 7.446

3.  Macrocyclic Gq Protein Inhibitors FR900359 and/or YM-254890-Fit for Translation?

Authors:  Jonathan G Schlegel; Mariam Tahoun; Alexander Seidinger; Jan H Voss; Markus Kuschak; Stefan Kehraus; Marion Schneider; Michaela Matthey; Bernd K Fleischmann; Gabriele M König; Daniela Wenzel; Christa E Müller
Journal:  ACS Pharmacol Transl Sci       Date:  2021-02-19

4.  Potent Antimalarials with Development Potential Identified by Structure-Guided Computational Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series.

Authors:  Michael J Palmer; Xiaoyi Deng; Shawn Watts; Goran Krilov; Aleksey Gerasyuto; Sreekanth Kokkonda; Farah El Mazouni; John White; Karen L White; Josefine Striepen; Jade Bath; Kyra A Schindler; Tomas Yeo; David M Shackleford; Sachel Mok; Ioanna Deni; Aloysus Lawong; Ann Huang; Gong Chen; Wen Wang; Jaya Jayaseelan; Kasiram Katneni; Rahul Patil; Jessica Saunders; Shatrughan P Shahi; Rajesh Chittimalla; Iñigo Angulo-Barturen; María Belén Jiménez-Díaz; Sergio Wittlin; Patrick K Tumwebaze; Philip J Rosenthal; Roland A Cooper; Anna Caroline Campos Aguiar; Rafael V C Guido; Dhelio B Pereira; Nimisha Mittal; Elizabeth A Winzeler; Diana R Tomchick; Benoît Laleu; Jeremy N Burrows; Pradipsinh K Rathod; David A Fidock; Susan A Charman; Margaret A Phillips
Journal:  J Med Chem       Date:  2021-04-20       Impact factor: 7.446

5.  Ultrasensitive detection of malignant melanoma using PET molecular imaging probes.

Authors:  Ayoung Pyo; Dong-Yeon Kim; Heejung Kim; Daejin Lim; Seong Young Kwon; Sae-Ryung Kang; Hyung-Seok Kim; Hee-Seung Bom; Jung-Joon Min
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-21       Impact factor: 11.205

6.  Site-Specific, Stoichiometric-Controlled, PEGylated Conjugates of Fibroblast Growth Factor 2 (FGF2) with Hydrophilic Auristatin Y for Highly Selective Killing of Cancer Cells Overproducing Fibroblast Growth Factor Receptor 1 (FGFR1).

Authors:  Mateusz Adam Krzyscik; Małgorzata Zakrzewska; Jacek Otlewski
Journal:  Mol Pharm       Date:  2020-06-16       Impact factor: 4.939

7.  Development of a Web-Based Toolbox to Support Quantitative In-Vitro-to-In-Vivo Extrapolations (QIVIVE) within Nonanimal Testing Strategies.

Authors:  Ans Punt; Nicole Pinckaers; Ad Peijnenburg; Jochem Louisse
Journal:  Chem Res Toxicol       Date:  2020-12-31       Impact factor: 3.739

8.  Exploring the new potential antiviral constituents of Moringa oliefera for SARS-COV-2 pathogenesis: An in silico molecular docking and dynamic studies.

Authors:  Shabbir Muhammad; Sayyeda Hira Hassan; Abdullah G Al-Sehemi; Hafiz Abdullah Shakir; Muhammad Khan; Muhammad Irfan; Javed Iqbal
Journal:  Chem Phys Lett       Date:  2021-01-26       Impact factor: 2.328

9.  An in vitro toolbox to accelerate anti-malarial drug discovery and development.

Authors:  Susan A Charman; Alice Andreu; Helena Barker; Scott Blundell; Anna Campbell; Michael Campbell; Gong Chen; Francis C K Chiu; Elly Crighton; Kasiram Katneni; Julia Morizzi; Rahul Patil; Thao Pham; Eileen Ryan; Jessica Saunders; David M Shackleford; Karen L White; Lisa Almond; Maurice Dickins; Dennis A Smith; Joerg J Moehrle; Jeremy N Burrows; Nada Abla
Journal:  Malar J       Date:  2020-01-02       Impact factor: 2.979

10.  Population pharmacokinetic modeling of molibresib and its active metabolites in patients with solid tumors: A semimechanistic autoinduction model.

Authors:  Anu Shilpa Krishnatry; Alexander Voelkner; Arindam Dhar; Marita Prohn; Geraldine Ferron-Brady
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.